Cor Vasa 2011, 53(8-9):449-453 | DOI: 10.33678/cor.2011.113

Is target organ damage more frequent in primary aldosteronism than in essential hypertension?

Tomáš Indra*, Robert Holaj
Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze, III. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

Primary aldosteronism represents one of the common causes of secondary hypertension. Contrary to former assumptions, recent studies proved not only much greater prevalence of the disease among hypertensive population, but also increased risk of cardiovascular and renal damage in comparison with essential hypertension. However, growing evidence constantly suggests, that the risk of cardiovascular and renal complications in primary aldosteronism could be significantly decreased by specific treatment, either surgical or medical. The possibility and good effectivity of this treatment shows the importance of early and correct diagnostics of primary aldosteronism in hypertensive patients.

Keywords: Primary aldosteronism; Hypertension; Target organ damage; Cardiovascular risk

Published: August 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Indra T, Holaj R. Is target organ damage more frequent in primary aldosteronism than in essential hypertension? Cor Vasa. 2011;53(8-9):449-453. doi: 10.33678/cor.2011.113.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Plouin P-Fo, Amar L, Chatellier G, et al. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004;19:774-777. Go to original source... Go to PubMed...
    2. Mulatero P, Stowasser M, Loh K-C, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrin Metab 2004;89:1045-1050. Go to original source... Go to PubMed...
    3. Štrauch B, Zelinka T, Hampf M, et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Human Hyper 2003;17:349-352. Go to original source... Go to PubMed...
    4. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004;22:251-255. Go to original source...
    5. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001;135:258-261. Go to original source...
    6. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964;107:159-172. Go to original source... Go to PubMed...
    7. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: The use of renin and aldosterone profiles. Am J Med 1973;55:261-274. Go to original source...
    8. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N York Acad Sci 2002;970:89-100. Go to original source...
    9. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-1068. Go to original source... Go to PubMed...
    10. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004;66:1-9. Go to original source... Go to PubMed...
    11. Rossi G, Boscaro M, Ronconi V, et al. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005;16:104-107. Go to original source... Go to PubMed...
    12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717. Go to original source... Go to PubMed...
    13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. Go to original source... Go to PubMed...
    14. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002;283:H1802-H1810. Go to original source... Go to PubMed...
    15. Weber K, Brilla C. Pathological hypertrophy and cardiac intersticium fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865. Go to original source...
    16. Neves MF, Amiri F, Virdis A, et al. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005;83:999-1006. Go to original source... Go to PubMed...
    17. Funder JW. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007;50:840-841. Go to original source... Go to PubMed...
    18. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci 2007;113:267-278. Go to original source... Go to PubMed...
    19. Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008;52:529-534. Go to original source... Go to PubMed...
    20. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008;168:80-85. Go to original source... Go to PubMed...
    21. Rossi GP, Sacchetto A, Pavan E et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95:1471-1478. Go to original source...
    22. Shigematsu Y, Hamada M, Okayama H, et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29:723-727. Go to original source...
    23. Rizzoni D, Porteri E, Castellano M, et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996;28:785-790. Go to original source... Go to PubMed...
    24. Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrin Metab 2006;91:2638-2642. Go to original source... Go to PubMed...
    25. Štrauch B, Petrák O, Wichterle D, et al. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006;19:909-914. Go to original source... Go to PubMed...
    26. Holaj R, Zelinka T, Wichterle D, et al. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007;25:1451-1457. Go to original source... Go to PubMed...
    27. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Molecul Cell Cardiol 2000;32:865-879. Go to original source... Go to PubMed...
    28. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23-27. Go to original source...
    29. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007;50:911-918. Go to original source... Go to PubMed...
    30. Rizzoni D, Muiesan ML, Porteri E, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998;32:985-992. Go to original source...
    31. Yoshihara F, Nishikimi T, Yoshitomi Y, et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens 1996;9:523-528. Go to original source...
    32. Goldkorn R, Yurenev A, Blumenfeld J, et al. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. Am J Hypertens 2002;15:340-345. Go to original source...
    33. Milliez P, Girerd X, Plouin P-F, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248. Go to original source... Go to PubMed...
    34. Steichen O, Amar L, Plouin P. Cardiovascular complications in patients with primary hyperaldosteronism: A controlled cross-sectional study: J Hypertens xx;28:e302-e303.
    35. Born-Frontsberg E, Reincke M, Rump LC, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: Results of the German Conn's Registry. J Clin Endocrin Metab 2009;94:1125-1130. Go to original source... Go to PubMed...
    36. Boixel C, Fontaine V, Rucker-Martin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003;42:336-344. Go to original source...
    37. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-2706. Go to original source...
    38. Ramires FJA, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-1211. Go to original source...
    39. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-1334. Go to original source...
    40. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-1376. Go to original source... Go to PubMed...
    41. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33:1111-1117. Go to original source...
    42. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrin Metab 2006;91:454-459. Go to original source... Go to PubMed...
    43. Iacobellis G, Petramala L, Cotesta D, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrin Metab xx;95:2391-2398. Go to original source...
    44. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: A follow-up study. J Clin Endocrin Metab 2006;91:3457-3463. Go to original source... Go to PubMed...
    45. Danforth Jr DN, Orlando MM, Bartter FC, et al. Renal changes in primary aldosteronism. J Urol 1977;117:140-144. Go to original source... Go to PubMed...
    46. Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999;33:261-266. Go to original source... Go to PubMed...
    47. Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009;94:869-875. Go to original source... Go to PubMed...
    48. Halimi J-M, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995;13:1801-1802. Go to original source...
    49. Ribstein J, Du Cailar G, Fesler P, et al. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005;16:1320-1325. Go to original source... Go to PubMed...
    50. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. J Am Med Assoc 2006;295:2638-2645. Go to original source... Go to PubMed...
    51. Sechi LA, Di Fabio A, Bazzocchi M, et al. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrin Metab 2009;94:1191-1197. Go to original source... Go to PubMed...
    52. Catena C, Colussi G, Nadalini E, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2007;2:722-731. Go to original source... Go to PubMed...
    53. Sechi LA, Colussi G, Di Fabio A, et al. Cardiovascular and renal damage in primary aldosteronism: Outcomes after treatment. Am J Hypertens xx;23:1253-1260. Go to original source...
    54. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-951. Go to original source... Go to PubMed...
    55. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005;46:45-51. Go to original source... Go to PubMed...
    56. Kozakova M, Buralli S, Palombo C, et al. Myocardial ultrasonic backscatter in hypertension: Relation to aldosterone and endothelin. Hypertension 2003;41:230-236. Go to original source... Go to PubMed...
    57. Matsumura K, Fujii K, Oniki H, et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006;19:13-18. Go to original source... Go to PubMed...
    58. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005;90:5070-5076. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes